/PRVA
PRVA Stock - Privia Health Group, Inc.
Healthcare|Medical - Healthcare Information ServicesNASDAQ
$23.64-1.25%
$0.30 (-1.25%) • Dec 19
70
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.49
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).87
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.87
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+18.4%upside
Target: $27.99
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for PRVA
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$23.40 – $23.88
TARGET (TP)$28.00
STOP LOSS$21.75
RISK/REWARD1:2.3
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.83
52W High$26.51
52W Low$18.77
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $1.74B | $1.66B | $1.36B | $966.22M | $817.08M |
| Gross Profit | $176.85M | $161.50M | $134.78M | $63.66M | $82.58M |
| Gross Margin | 10.2% | 9.7% | 9.9% | 6.6% | 10.1% |
| Operating Income | $16.98M | $20.65M | $-19,122,000 | $-217,436,000 | $25.38M |
| Net Income | $14.38M | $23.08M | $-8,585,000 | $-188,230,000 | $31.24M |
| Net Margin | 0.8% | 1.4% | -0.6% | -19.5% | 3.8% |
| EPS | $0.12 | $0.20 | $-0.11 | $-1.77 | $0.30 |
Company Overview
Privia Health Group, Inc. operates as a national physician-enablement company in the United States. The company collaborates with medical groups, health plans, and health systems to optimize physician practices, enhance patient experiences, and reward doctors for delivering care in-person and virtual settings. It offers technology and population health tools to enhance independent providers' workflows; management services organization that enable providers to focus on their patients by reducing administrative work; single-TIN medical group that facilitates payer negotiation, clinical integration and alignment of financial incentives; accountable care organization, which engage patients, reduce inappropriate utilization, and enhance coordination and patient quality metrics to drive value-based care; and network for purchasers and payers that enable providers to connect with new patient populations and create custom contracts. The company was founded in 2007 and is headquartered in Arlington, Virginia. Privia Health Group, Inc. was a former subsidiary of Brighton Health Group Holdings, LLC.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
15
88%
Hold / Neutral
2
12%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
15 Bullish2 Neutral/Bearish
Price Targets
$29
Average Target
↑ 24.6% Upside
Now
$21
Low
$29
Average
$54
High
Based on 18 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| November 13th 2025 | BMO Capital Markets | Initiation | Outperform | $30 |
| January 10th 2025 | Needham | Initiation | Buy | $25 |
| December 16th 2024 | Macquarie | Initiation | Outperform | - |
| October 11th 2024 | KeyBanc Capital Markets | Initiation | Overweight | $23 |
| May 30th 2024 | Robert W. Baird | Initiation | Outperform | $23 |
| April 22nd 2024 | Citigroup | Initiation | Buy | $25 |
| March 6th 2024 | Barclays | Initiation | Equal Weight | $22 |
| February 26th 2024 | Jefferies | Resumed | Buy | $25← $33 |
| February 22nd 2024 | BofA Securities | Downgrade | Neutral | $21 |
| December 6th 2023 | JMP Securities | Initiation | Mkt Outperform | $27 |
| June 13th 2023 | Evercore ISI | Initiation | Outperform | $34 |
| April 12th 2023 | Stephens | Initiation | Overweight | $33 |
| March 10th 2023 | RBC Capital Mkts | Initiation | Outperform | $36 |
| February 3rd 2023 | Goldman | Initiation | Buy | $32 |
| December 9th 2022 | Stifel | Initiation | Buy | $28 |
Earnings History & Surprises
PRVABeat Rate
39%
Last 18 quarters
Avg Surprise
+44.1%
EPS vs Estimate
Beats / Misses
7/9
2 met exactly
Latest EPS
$0.05
Q4 2025
EPS Surprise History
Q1 24
-52.7%
$0.02vs$0.04
Q2 24
-60.0%
$0.02vs$0.05
Q3 24
-40.0%
$0.03vs$0.05
Q4 24
-40.0%
$0.03vs$0.05
Q1 25
-40.0%
$0.03vs$0.05
Q2 25
-50.0%
$0.03vs$0.06
Q3 25
-60.0%
$0.02vs$0.05
Q4 25
-16.7%
$0.05vs$0.06
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 6, 2026 | — | — | — | — |
Q1 2026 | Feb 26, 2026 | $0.04 | — | — | — |
Q4 2025 | Nov 6, 2025 | $0.06 | $0.05 | -16.7% | ✗ MISS |
Q3 2025 | Aug 7, 2025 | $0.05 | $0.02 | -60.0% | ✗ MISS |
Q2 2025 | May 8, 2025 | $0.06 | $0.03 | -50.0% | ✗ MISS |
Q1 2025 | Feb 27, 2025 | $0.05 | $0.03 | -40.0% | ✗ MISS |
Q4 2024 | Nov 7, 2024 | $0.05 | $0.03 | -40.0% | ✗ MISS |
Q3 2024 | Aug 8, 2024 | $0.05 | $0.03 | -40.0% | ✗ MISS |
Q2 2024 | May 9, 2024 | $0.05 | $0.02 | -60.0% | ✗ MISS |
Q1 2024 | Feb 27, 2024 | $0.04 | $0.02 | -52.7% | ✗ MISS |
Q4 2023 | Nov 3, 2023 | $0.05 | $0.05 | 0.0% | = MET |
Q3 2023 | Aug 3, 2023 | $0.06 | $0.06 | 0.0% | = MET |
Q2 2023 | May 4, 2023 | $0.02 | $0.06 | +228.8% | ✓ BEAT |
Q1 2023 | Feb 28, 2023 | $0.02 | $0.14 | +606.4% | ✓ BEAT |
Q4 2022 | Nov 10, 2022 | $0.00 | $0.01 | +109.2% | ✓ BEAT |
Q3 2022 | Aug 11, 2022 | $-0.01 | $-0.10 | -636.4% | ✗ MISS |
Q2 2022 | May 12, 2022 | $-0.05 | $0.12 | +340.4% | ✓ BEAT |
Q1 2022 | Mar 22, 2022 | $-0.11 | $0.06 | +154.5% | ✓ BEAT |
Q4 2021 | Nov 8, 2021 | $-0.09 | $0.13 | +244.4% | ✓ BEAT |
Q3 2021 | Aug 9, 2021 | $-1.66 | $0.09 | +105.4% | ✓ BEAT |
Latest News
Stephens & Co. Reiterates Overweight on Privia Health Gr, Maintains $32 Price Target
📈 PositiveBenzinga•Dec 4, 2025, 02:16 PM
JP Morgan Maintains Overweight on Privia Health Gr, Raises Price Target to $33
📈 PositiveBenzinga•Nov 13, 2025, 06:55 PM
BMO Capital Initiates Coverage On Privia Health Gr with Outperform Rating, Announces Price Target of $30
📈 PositiveBenzinga•Nov 13, 2025, 09:44 AM
Canaccord Genuity Maintains Buy on Privia Health Gr, Raises Price Target to $34
📈 PositiveBenzinga•Nov 12, 2025, 01:06 PM•Also:
Barclays Maintains Equal-Weight on Privia Health Gr, Raises Price Target to $23
📈 PositiveBenzinga•Nov 10, 2025, 07:07 PM•Also:
Truist Securities Reiterates Buy on Privia Health Gr, Raises Price Target to $31
📈 PositiveBenzinga•Nov 10, 2025, 05:05 PM
Evercore ISI Group Maintains Outperform on Privia Health Gr, Raises Price Target to $30
📈 PositiveBenzinga•Nov 7, 2025, 02:45 PM
Citizens Maintains Market Outperform on Privia Health Gr, Raises Price Target to $31
📈 PositiveBenzinga•Nov 7, 2025, 02:11 PM
Privia Health Gr Raises FY2025 Sales Guidance from $1.800B-$1.900B to $2.050B-$2.100B vs $3.359B Est
➖ NeutralBenzinga•Nov 6, 2025, 11:02 AM
Privia Health Gr Q3 Adj. EPS $0.29 Beats $0.05 Estimate, Sales $580.400M Miss $781.946M Estimate
➖ NeutralBenzinga•Nov 6, 2025, 11:01 AM
Barclays Maintains Equal-Weight on Privia Health Gr, Raises Price Target to $22
📈 PositiveBenzinga•Oct 9, 2025, 12:22 PM•Also:
Evolent Health shares are trading higher after the company announced that it has agreed to sell its value-based primary care business, Evolent Care Partners, to Privia Health Group.
📈 PositiveBenzinga•Sep 24, 2025, 03:17 PM•Also:
Stephens & Co. Reiterates Overweight on Privia Health Gr, Maintains $32 Price Target
📈 PositiveBenzinga•Sep 24, 2025, 12:30 PM
Evolent Announces Divestiture Of Its Evolent Care Partners Primary Care Business To Privia, Total Transaction Value Up To $113M; Co. Reiterates Q3 Outlook, Says Proceeds Will Be Used To Prepay Senior Term Debt
📈 PositiveBenzinga•Sep 23, 2025, 08:11 PM•Also:
Stephens & Co. Reiterates Overweight on Privia Health Gr, Maintains $32 Price Target
📈 PositiveBenzinga•Sep 4, 2025, 12:54 PM
JMP Securities Maintains Market Outperform on Privia Health Gr, Raises Price Target to $30
📈 PositiveBenzinga•Aug 29, 2025, 04:46 PM
Frequently Asked Questions about PRVA
What is PRVA's current stock price?
Privia Health Group, Inc. (PRVA) is currently trading at $23.64 per share. The stock has moved -1.25% today.
What is the analyst price target for PRVA?
The average analyst price target for PRVA is $28.00, based on 1 analyst.
What sector is Privia Health Group, Inc. in?
Privia Health Group, Inc. operates in the Healthcare sector, specifically within the Medical - Healthcare Information Services industry. The company is traded on the NASDAQ exchange.
What is PRVA's market cap?
Privia Health Group, Inc. has a market capitalization of $2.91 billion, making it a mid-cap company.
Does PRVA pay dividends?
No, Privia Health Group, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorARQT
Arcutis Biotherapeutics, Inc.
$28.01
Mkt Cap: $3.4B
ATEC
Alphatec Holdings, Inc.
$20.01
Mkt Cap: $3.0B
HTFL
Heartflow, Inc. Common Stock
$30.51
Mkt Cap: $2.6B
ICUI
ICU Medical, Inc.
$145.15
Mkt Cap: $3.6B
LIVN
LivaNova PLC
$62.82
Mkt Cap: $3.4B
NVST
Envista Holdings Corp
$22.28
Mkt Cap: $3.7B
PBH
Prestige Consumer Healthcare Inc.
$61.74
Mkt Cap: $3.1B
PINC
Premier, Inc.
$28.26
Mkt Cap: $2.3B
SUPN
Supernus Pharmaceuticals, Inc.
$51.48
Mkt Cap: $2.9B
TVTX
Travere Therapeutics, Inc.
$34.51
Mkt Cap: $3.1B
Explore stocks similar to PRVA for comparison